LIXTE Biotechnology Holdings (NASDAQ: LIXT) reported its first-quarter 2026 financial results and operational highlights, emphasizing progress in its oncology pipeline and strategic expansion. The company's lead candidate, LB-100, a first-in-class PP2A inhibitor, continues to advance in clinical trials, including an expanded ovarian cancer trial following favorable safety data in combination with immunotherapy. Additionally, LIXTE reported continued growth at its recently acquired subsidiary, Liora Technologies Europe, which develops proton therapy systems for cancer treatment.
LB-100 is being evaluated for its potential to enhance chemotherapies and immunotherapies, based on published preclinical data. The compound targets a novel approach in cancer biology known as activation lethality, representing a new treatment paradigm. LIXTE currently has proof-of-concept clinical trials underway for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma. The company's patent portfolio covers this innovative approach.
Through its wholly owned subsidiary, Liora Technologies Europe, LIXTE is also pioneering electronically controlled proton therapy systems. Liora's proprietary LiGHT System is believed to offer significant advantages over existing proton therapy technologies for treating various tumors. The subsidiary's growth contributes to LIXTE's broader strategic expansion to strengthen its oncology pipeline and treatment development capabilities.
For more details on the first-quarter results, the full press release is available at https://ibn.fm/oHzhK. Additional information about LIXTE and its subsidiaries can be found at www.lixte.com and www.lioratechnologies.com.
The latest news and updates on LIXT are available in the company's newsroom at https://ibn.fm/LIXT.
